Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2010

Open Access 01-12-2010 | Primary research

Activating Transcription Factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination

Authors: Carly St Germain, Anna O'Brien, Jim Dimitroulakos

Published in: Cancer Cell International | Issue 1/2010

Login to get access

Abstract

Background

Activating Transcription Factor (ATF) 3 is a key regulator of the cellular integrated stress response whose expression has also been correlated with pro-apoptotic activities in tumour cell models. Combination treatments with chemotherapeutic drugs, such as cisplatin, and histone deacetylase (HDAC) inhibitors have been demonstrated to enhance tumour cell cytotoxicity. We recently demonstrated a role for ATF3 in regulating cisplatin-induced apoptosis and others have shown that HDAC inhibition can also induce cellular stress. In this study, we evaluated the role of ATF3 in regulating the co-operative cytotoxicity of cisplatin in combination with an HDAC inhibitor.

Results

The HDAC inhibitor M344 induced ATF3 expression at the protein and mRNA level in a panel of human derived cancer cell lines as determined by Western blot and quantitative RT-PCR analyses. Combination treatment with M344 and cisplatin lead to increased induction of ATF3 compared with cisplatin alone. Utilizing the MTT cell viability assay, M344 treatments also enhanced the cytotoxic effects of cisplatin in these cancer cell lines. The mechanism of ATF3 induction by M344 was found to be independent of MAPKinase pathways and dependent on ATF4, a known regulator of ATF3 expression. ATF4 heterozygote (+/-) and knock out (-/-) mouse embryonic fibroblast (MEF) as well as chromatin immunoprecipitation (ChIP) assays were utilized in determining the mechanistic induction of ATF3 by M344. We also demonstrated that ATF3 regulates the enhanced cytotoxicity of M344 in combination with cisplatin as evidenced by attenuation of cytotoxicity in shRNAs targeting ATF3 expressing cells.

Conclusion

This study identifies the pro-apoptotic factor, ATF3 as a novel target of M344, as well as a mediator of the co-operative effects of cisplatin and M344 induced tumour cell cytotoxicity.
Appendix
Available only for authorised users
Literature
1.
Carew JS, Giles FJ, Nawrocki ST: Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008, 269 (1): 7-17. 10.1016/j.canlet.2008.03.037.CrossRefPubMed
2.
Ma X, Ezzeldin HH, Diasio RB: Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs. 2009, 69 (14): 1911-1934. 10.2165/11315680-000000000-00000.CrossRefPubMed
3.
Xu WS, Parmigiani RB, Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007, 26 (37): 5541-5552. 10.1038/sj.onc.1210620.CrossRefPubMed
4.
5.
Duvic M, Vu J: Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2007, 16 (7): 1111-1120. 10.1517/13543784.16.7.1111.CrossRefPubMed
6.
Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007, 7 (8): 573-584. 10.1038/nrc2167.CrossRefPubMed
7.
Stewart DJ: Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol. 2007, 63 (1): 12-31. 10.1016/j.critrevonc.2007.02.001.CrossRefPubMed
8.
Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003, 22 (47): 7265-7279. 10.1038/sj.onc.1206933.CrossRefPubMed
9.
Noguchi H, Yamashita H, Murakami T, Hirai K, Noguchi Y, Maruta J, Yokoi T, Noguchi S: Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocr J. 2009, 56 (2): 245-249. 10.1507/endocrj.K08E-016.CrossRefPubMed
10.
Pauer LR, Olivares J, Cunningham C, Williams A, Grove W, Kraker A, Olson S, Nemunaitis J: Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest. 2004, 22 (6): 886-896. 10.1081/CNV-200039852.CrossRefPubMed
11.
Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ: Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res. 2007, 13 (12): 3605-3610. 10.1158/1078-0432.CCR-07-0162.CrossRefPubMed
12.
Ozaki K, Kishikawa F, Tanaka M, Sakamoto T, Tanimura S, Kohno M: Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci. 2008, 99 (2): 376-384. 10.1111/j.1349-7006.2007.00669.x.CrossRefPubMed
13.
Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003, 63 (21): 7291-7300.PubMed
14.
Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, Scherpereel A, Willems L: Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res. 2009, 15 (8): 2818-2828. 10.1158/1078-0432.CCR-08-1579.CrossRefPubMed
15.
Bandyopadhyay K, Baneres JL, Martin A, Blonski C, Parello J, Gjerset RA: Spermidinyl-CoA-based HAT inhibitors block DNA repair and provide cancer-specific chemo- and radiosensitization. Cell Cycle. 2009, 8 (17): 2779-2788. 10.4161/cc.8.17.9416.PubMedCentralCrossRefPubMed
16.
Shen J, Huang C, Jiang L, Gao F, Wang Z, Zhang Y, Bai J, Zhou H, Chen Q: Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem Pharmacol. 2007, 73 (12): 1901-1909. 10.1016/j.bcp.2007.03.009.CrossRefPubMed
17.
Lin CT, Lai HC, Lee HY, Lin WH, Chang CC, Chu TY, Lin YW, Lee KD, Yu MH: Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci. 2008, 99 (6): 1218-1226. 10.1111/j.1349-7006.2008.00793.x.CrossRefPubMed
18.
Rikiishi H, Shinohara F, Sato T, Sato Y, Suzuki M, Echigo S: Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int J Oncol. 2007, 30 (5): 1181-1188.PubMed
19.
St Germain C, Niknejad N, Ma L, Garbuio K, Hai T, Dimitroulakos J: Cisplatin induces cytotoxicity through the Mitogen-Activated Protein Kinase pathways and activating transcription factor 3. Neoplasia. 2010, 12 (7): 527-538.PubMedCentralCrossRefPubMed
20.
Hai T, Hartman MG: The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene. 2001, 273 (1): 1-11. 10.1016/S0378-1119(01)00551-0.CrossRefPubMed
21.
Hsu JC, Laz T, Mohn KL, Taub R: Identification of LRF-1, a leucine-zipper protein that is rapidly and highly induced in regenerating liver. Proc Natl Acad Sci USA. 1991, 88 (9): 3511-3515. 10.1073/pnas.88.9.3511.PubMedCentralCrossRefPubMed
22.
Chen BP, Wolfgang CD, Hai T: Analysis of ATF3, a transcription factor induced by physiological stresses and modulated by gadd153/Chop10. Mol Cell Biol. 1996, 16 (3): 1157-1168.PubMedCentralCrossRefPubMed
23.
Yin T, Sandhu G, Wolfgang CD, Burrier A, Webb RL, Rigel DF, Hai T, Whelan J: Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney. J Biol Chem. 1997, 272 (32): 19943-19950. 10.1074/jbc.272.32.19943.CrossRefPubMed
24.
Takeda M, Kato H, Takamiya A, Yoshida A, Kiyama H: Injury-specific expression of activating transcription factor-3 in retinal ganglion cells and its colocalized expression with phosphorylated c-Jun. Invest Ophthalmol Vis Sci. 2000, 41 (9): 2412-2421.PubMed
25.
Yin X, Dewille JW, Hai T: A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development. Oncogene. 2008, 27 (15): 2118-2127. 10.1038/sj.onc.1210861.CrossRefPubMed
26.
Fan W, Jin S, Tong T, Zhao H, Fan F, Antinore MJ, Rajasekaran B, Wu M, Zhan Q: BRCA1 regulates GADD45 through its interactions with the OCT-1 and CAAT motifs. J Biol Chem. 2002, 277 (10): 8061-8067. 10.1074/jbc.M110225200.CrossRefPubMed
27.
Bottone FG, Moon Y, Kim JS, Alston-Mills B, Ishibashi M, Eling TE: The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3). Mol Cancer Ther. 2005, 4 (5): 693-703. 10.1158/1535-7163.MCT-04-0337.CrossRefPubMed
28.
Lu D, Wolfgang CD, Hai T: Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis. J Biol Chem. 2006, 281 (15): 10473-10481. 10.1074/jbc.M509278200.CrossRefPubMed
29.
Zhang C, Gao C, Kawauchi J, Hashimoto Y, Tsuchida N, Kitajima S: Transcriptional activation of the human stress-inducible transcriptional repressor ATF3 gene promoter by p53. Biochem Biophys Res Commun. 2002, 297 (5): 1302-1310. 10.1016/S0006-291X(02)02382-3.CrossRefPubMed
30.
Buganim Y, Kalo E, Brosh R, Besserglick H, Nachmany I, Rais Y, Stambolsky P, Tang X, Milyavsky M, Shats I: Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction. Cancer Res. 2006, 66 (22): 10750-10759. 10.1158/0008-5472.CAN-06-0916.CrossRefPubMed
31.
Wek RC, Jiang HY, Anthony TG: Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans. 2006, 34 (Pt 1): 7-11.CrossRefPubMed
32.
Lu D, Chen J, Hai T: The regulation of ATF3 gene expression by mitogen-activated protein kinases. Biochem J. 2007, 401 (2): 559-567. 10.1042/BJ20061081.PubMedCentralCrossRefPubMed
33.
Hamdi M, Popeijus HE, Carlotti F, Janssen JM, van der Burgt C, Cornelissen-Steijger P, van de Water B, Hoeben RC, Matsuo K, van Dam H: ATF3 and Fra1 have opposite functions in JNK- and ERK-dependent DNA damage responses. DNA Repair (Amst). 2008, 7 (3): 487-496. 10.1016/j.dnarep.2007.12.004.CrossRef
34.
Niknejad N, Morley M, Dimitroulakos J: Activation of the integrated stress response regulates lovastatin-induced apoptosis. J Biol Chem. 2007, 282 (41): 29748-29756. 10.1074/jbc.M705859200.CrossRefPubMed
35.
Chiba T, Yokosuka O, Arai M, Tada M, Fukai K, Imazeki F, Kato M, Seki N, Saisho H: Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells. J Hepatol. 2004, 41 (3): 436-445. 10.1016/j.jhep.2004.05.018.CrossRefPubMed
36.
Jiang HY, Wek SA, McGrath BC, Lu D, Hai T, Harding HP, Wang X, Ron D, Cavener DR, Wek RC: Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol Cell Biol. 2004, 24 (3): 1365-1377. 10.1128/MCB.24.3.1365-1377.2004.PubMedCentralCrossRefPubMed
37.
Wilson AJ, Chueh AC, Togel L, Corner GA, Ahmed N, Goel S, Byun DS, Nasser S, Houston MA, Jhawer M: Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. Cancer Res. 2010, 70 (2): 609-620. 10.1158/0008-5472.CAN-09-2327.PubMedCentralCrossRefPubMed
38.
Yu C, Dasmahapatra G, Dent P, Grant S: Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. Leukemia. 2005, 19 (9): 1579-1589. 10.1038/sj.leu.2403868.CrossRefPubMed
39.
Kahali S, Sarcar B, Fang B, Williams ES, Koomen JM, Tofilon PJ, Chinnaiyan P: Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat. Neoplasia. 2010, 12 (1): 80-86.PubMedCentralCrossRefPubMed
40.
Wolfgang CD, Chen BP, Martindale JL, Holbrook NJ, Hai T: gadd153/Chop10, a potential target gene of the transcriptional repressor ATF3. Mol Cell Biol. 1997, 17 (11): 6700-6707.PubMedCentralCrossRefPubMed
41.
Allan AL, Albanese C, Pestell RG, LaMarre J: Activating transcription factor 3 induces DNA synthesis and expression of cyclin D1 in hepatocytes. J Biol Chem. 2001, 276 (29): 27272-27280. 10.1074/jbc.M103196200.CrossRefPubMed
42.
Frew AJ, Johnstone RW, Bolden JE: Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett. 2009, 280 (2): 125-133. 10.1016/j.canlet.2009.02.042.CrossRefPubMed
43.
Suzuki M, Endo M, Shinohara F, Echigo S, Rikiishi H: Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells. Cancer Chemother Pharmacol. 2009, 64 (6): 1115-1122. 10.1007/s00280-009-0969-x.CrossRefPubMed
Metadata
Title
Activating Transcription Factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination
Authors
Carly St Germain
Anna O'Brien
Jim Dimitroulakos
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2010
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-10-32

Other articles of this Issue 1/2010

Cancer Cell International 1/2010 Go to the issue

Primary research

CCAAT/Enhancer Binding Protein-delta (C/EBP-delta) regulates cell growth, migration and differentiation

Hypothesis

Exploration of the postponing mechanism that delays carcinoma onset

Primary research

MicroRNA-26a-mediated regulation of interleukin-2 expression in transformed avian lymphocyte lines

Primary research

Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies

Primary research

α-TEA-induced death receptor dependent apoptosis involves activation of acid sphingomyelinase and elevated ceramide-enriched cell surface membranes

Primary research

Up-regulation of p21 and TNF-α is mediated in lycorine-induced death of HL-60 cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits